➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKesson
McKinsey
Johnson and Johnson
AstraZeneca

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209022


Email this page to a colleague

« Back to Dashboard

NDA 209022 describes XHANCE, which is a drug marketed by Optinose Us Inc and is included in one NDA. There are fourteen patents protecting this drug. Additional details are available on the XHANCE profile page.

The generic ingredient in XHANCE is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
Summary for 209022
Tradename:XHANCE
Applicant:Optinose Us Inc
Ingredient:fluticasone propionate
Patents:14
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrength0.093MG
Approval Date:Sep 18, 2017TE:RLD:Yes
Patent:⤷  Free Forever TrialPatent Expiration:Oct 20, 2034Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Free Forever TrialPatent Expiration:Jul 30, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
Patent:⤷  Free Forever TrialPatent Expiration:Mar 6, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Expired US Patents for NDA 209022

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 ⤷  Free Forever Trial ⤷  Free Forever Trial
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 ⤷  Free Forever Trial ⤷  Free Forever Trial
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 ⤷  Free Forever Trial ⤷  Free Forever Trial
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Boehringer Ingelheim
Johnson and Johnson
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.